Strides Pharma jumps 11% after USFDA EIR clearance

Strides Pharma jumps 11% after USFDA EIR clearance. The USFDA issued an Establishment Inspection Report (EIR) for its flagship Bengaluru facility, signaling progress toward compliance resolution. This clears a key regulatory hurdle for resuming US market shipments. The positive sentiment boosted investor confidence in its revival.

📊 STOCKS: STRAIDSPHARM | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA